Monday, December 23, 2024
HomeTagsJAK1/JAK2 inhibitor

JAK1/JAK2 inhibitor

Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets

Incyte announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor,...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics